[CAS NO. 1346242-81-6] Erdafitinib (JNJ-42756493)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1346242-81-6]

Catalog

SLK-S8401

Brand

Selleck

CAS

1346242-81-6

DESCRIPTION [1346242-81-6]

Overview

MDL	MFCD28502040
Molecular Weight	446.54
Molecular Formula	C25H30N6O2
SMILES	N(CCNC(C)C)(C1=CC2=C(C=C1)N=CC(=N2)C3=CN(C)N=C3)C4=CC(OC)=CC(OC)=C4

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.2394 mL	11.1972 mL	22.3944 mL
5 mM	0.4479 mL	2.2394 mL	4.4789 mL
10 mM	0.2239 mL	1.1197 mL	2.2394 mL
50 mM	0.0448 mL	0.2239 mL	0.4479 mL

Description

Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan inhibitor with potential antineoplastic activity. Erdafitinib also binds to , , , , and and induces cellular .

Targets

In vitro

JNJ-42756493 is a potent, oral pan-FGFR tyrosine kinase inhibitor with half-maximal inhibitory concentration values in the low nanomolar range for all members of the FGFR family (FGFR1 to FGFR4), with minimal activity on vascular endothelial growth factor receptor (VEGFR) kinases compared with FGFR kinases (approximately 20-fold potency difference). In vitro, the proliferation of cells treated with JNJ-42756493 is decreased, associated with increased apoptotic death and decreased cell survival.

References

[1] Timothy Perera, et al. Cancer Res. 2014, 74(19 Suppl):Abstract nr 1738.
[2] Verstraete M, et al. BMC Cancer. 2015, 15:946.
[3] K S Hanna. Drugs Today (Barc). 2019 Aug;55(8):495-501.

Synonyms

1,2-Ethanediamine, N¹-(3,5-dimethoxyphenyl)-N²-(1-methylethyl)-N¹-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-

N¹-(3,5-Dimethoxyphenyl)-N²-(1-methylethyl)-N¹-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine

Erdafitinib

JNJ 42756493

Balversa